Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/18/2020 07:17 PST] NOVN Expected to Trade Up After Bullish Patterns Develop
• [01/16/2020 07:42 PST] NOVN Expected to Trade Up After Bullish Patterns Develop
• [01/13/2020 11:07 PST] Novan, Inc. (NASDAQ:NOVN), Down By 100.00% ($0.82) From $0.820 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [01/07/2020 07:54 PST] NOVN Expected to Trade Down After Bearish Patterns Develop
• [12/27/2019 07:50 PST] NOVN Expected to Trade Up After Bullish Patterns Develop
• [12/26/2019 11:45 PST] Novan, Inc. (NASDAQ:NOVN), Up By 100.00% ($2.80) From $2.800 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions